MedCity News July 21, 2019
Alaric DeArment

While well-developed in cancers, precision medicine’s readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.

More than a decade ago, the science fiction author William Gibson said, “The future is here – it’s just not evenly distributed.” It’s impossible to know exactly what went through his mind when he said that, but the statement could just as easily be applied to the field of precision medicine.

Much of the focus on precision medicine – which involves taking into account individual patients’ genetics, environment and lifestyle – has focused on cancers, especially with the rise of next-generation sequencing (NGS) and drugs that target specific biomarkers.

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Physician, Precision Medicine, Provider, Technology
Related Articles:
23andMe: What If …
23andMe CEO Anne Wojcicki considers taking company private
Age of Opportunity: Artificial Intelligence and the Precision Medicine Future
Opinion: Readers respond to OTC antidepressants, personalized medicine, restoring trust in public health, and more
Precision medicine approach combining AI, DNA and drug testing shows gains against relapsed childhood cancers

Share This Article